Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26491481 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL20876854 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL8372916 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| Tetrahydropellitorine SCHEMBL4878046 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL20883256 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL443535 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL7432688 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL1456461 | 1.00 | FAAH (0.64) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| SCHEMBL9462479 | 0.98 | FAAH (0.61) | FAAHMEN1MAPK1KMT2AEPHX1 | |
| Hydrochloric Acid SCHEMBL5396087 | 0.96 | FAAH (0.59) | FAAHMEN1MAPK1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592418-B1 | USE OF ENDOCANNABINOID-LIKE COMPOUNDS FOR TREATING CNS DEGENERATIVE DISORDERS | RES & INNOVATION S P A (IT) | 2017-09-06 | — | — | EP | disclosed |
| EP-3049462-A1 | VISCOELASTIC MATERIAL PRODUCED BY HYDROTHERMAL LIQUEFACTION OF MICROALGAE | IFSTTAR Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (FR) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015044891-A1 | VISCOELASTIC MATERIAL PRODUCED BY HYDROTHERMAL LIQUEFACTION OF MICROALGAE | IFSTTAR (FR) | 2015-04-02 | — | — | WO | disclosed |
| EP-1900365-B9 | Endocannabinoid-like compounds and their use for treating dermatitis | RES & INNOVATION S P A (IT) | 2012-01-18 | — | — | EP | disclosed |
| EP-1900365-B1 | Endocannabinoid-like compounds and their use for treating dermatitis | RES & INNOVATION S P A (IT) | 2011-03-30 | — | — | EP | disclosed |
| EP-1900365-A2 | New endocannabinoid-like compounds and their use | RESEARCH & INNOVATION SOC. COOP. A R.L. (IT) | 2008-03-19 | — | — | EP | disclosed |
| EP-1592418-A2 | USE IN THERAPY OF ENDOCANNABINOID-LIKE COMPOUNDS | Research & Innovation Soc. Coop. A R.L. (IT) | 2005-11-09 | — | — | EP | disclosed |
| US-6887921-B2 | Ink follower composition for writing instruments, and process for its production | THE PILOT INK CO., LTD. (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20050043536-A1 | antagonists of urotensin II; for example, 2,6-Dichloro-N-[3-(dimethylamino-ethoxy)4-trifluoromethyl-phenyl]-4trifluoromethyl-benzenesulfonamide | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2004069240-A2 | USE IN THERAPY OF ENDOCANNABINOID-LIKE COMPOUNDS | RESEARCH & INNOVATION SOC. COOP. A. R. L. (IT) | 2004-08-19 | — | — | WO | disclosed |
| US-20030200896-A1 | Ink follower composition for writing instruments, and process for its production | THE PILOT INK CO., LTD. (JP) | 2003-10-30 | — | — | US | disclosed |
| WO-1990003967-A1 | PROCESS FOR PRODUCING LIGHT-COLOURED SALTS OF ALKYLESTERS OF ALPHA-SULPHOFATTY ACIDS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1990-04-19 | — | — | WO | disclosed |
| EP-0363781-A1 | Process for the preparation of bright-coloured alpha-sulpho-fatty-acid alkyl ester salts | Henkel Kommanditgesellschaft auf Aktien (DE) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043536-A1 | antagonists of urotensin II; for example, 2,6-Dichloro-N-[3-(dimethylamino-ethoxy)4-trifluoromethyl-phenyl]-4trifluoromethyl-benzenesulfonamide | UTS2R, SPINT2, PRSS2 | FAAH 359/4885MEN1 4148/4885MAPK1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.